Costin Jeremy, Mouslim Morgane C, Socal Mariana P, Trujillo Antonio
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
The Hilltop Institute, University of Maryland, Baltimore County, Baltimore, MD, 21250, USA.
Pharmacoecon Open. 2024 Jan;8(1):115-118. doi: 10.1007/s41669-023-00447-6. Epub 2023 Nov 3.
We conducted a study to investigate the role of health insurance plans on biosimilar adoption among commercially insured patients in the USA. Flexible and rigid health plans may exhibit differing biosimilar coverage due to variations in cost considerations, formulary design, and provider networks.
To identify the characteristics of switchers and biosimilar initiators for six biologic-biosimilar pairs.
Using claims data from 2015 to 2019, we implement sequential regression models to assess the role of health plans on biosimilars adoption.
We found that low-flexibility plans, such as Health Maintenance Organization (HMOs) and Exclusive Provider Organization (EPOs), are more likely to have patients who are switchers and/or biosimilar initiators.
Our findings highlight the importance of health insurance plan design in promoting biosimilar uptake.
我们开展了一项研究，以调查医疗保险计划在美国商业保险患者中对生物类似药采用情况的作用。灵活和严格的健康计划可能因成本考量、处方集设计和供应商网络的差异而呈现出不同的生物类似药覆盖范围。
确定六对生物药-生物类似药组合的换药者和生物类似药起始使用者的特征。
利用2015年至2019年的理赔数据，我们实施了序贯回归模型，以评估健康计划对生物类似药采用情况的作用。
我们发现，低灵活性计划，如健康维护组织（HMO）和独家供应商组织（EPO），更有可能拥有换药者和/或生物类似药起始使用者。
我们的研究结果凸显了医疗保险计划设计在促进生物类似药使用方面的重要性。
